CIK: 0001703031 · Show all filings
Period: Q2 2020 (← Previous) (Next →)
Filing Date: Aug 14, 2020
Total Value ($000): $954,774 (100.0% shares, 0.0% debt)
| Ticker | Issuer | Shares | Value ($000) | % | Est. Cost | Unrealized | Class | CUSIP |
|---|---|---|---|---|---|---|---|---|
| — | SPRINGWORKS THERAPEUTICS INC | 7,281,307 | $305,815 | 32.0% | $21.68 | — | COM | 85205L107 |
| ARQT | ARCUTIS BIOTHERAPEUTICS, INC. | 3,979,292 | $120,334 | 12.6% | $26.87 | +7.6% | COM | 03969K108 |
| — | DICERNA PHARMACEUTICALS INC | 4,080,237 | $103,638 | 10.9% | $9.03 | — | COM | 253031108 |
| — | DYNAVAX TECHNOLOGIES CORP. | 10,895,773 | $96,646 | 10.1% | $4.63 | — | COM | 268158201 |
| — | MERSANA THERAPEUTICS, INC. | 3,445,667 | $80,629 | 8.4% | $23.40 | — | COM | 59045L106 |
| REPL | REPLIMUNE GROUP INC | 2,162,598 | $53,741 | 5.6% | $17.53 | +0.9% | COM | 76029N106 |
| — | CONSTELLATION PHARMACEUTICALS INC. | 1,400,000 | $42,070 | 4.4% | $47.11 | — | COM | 210373106 |
| — | AEGLEA BIOTHERAPEUTICS, INC. | 2,700,000 | $24,975 | 2.6% | $9.25 | — | COM | 00773J103 |
| — | APTINYX INC | 5,558,425 | $23,179 | 2.4% | $10.97 | — | COM | 03836N103 |
| SVRA | SAVARA INC | 5,128,593 | $22,976 | 2.4% | $1.20 | +102.1% | COM | 805111101 |
| — | SAGE THERAPEUTICS, INC. | 499,100 | $20,753 | 2.2% | $41.58 | — | COM | 78667J108 |
| CRNX | CRINETICS PHARMACEUTICALS, INC. | 1,071,428 | $18,771 | 2.0% | $17.05 | 0.0% | COM | 22663K107 |
| — | X4 PHARMACEUTICALS INC | 1,648,485 | $15,364 | 1.6% | $10.70 | — | COM | 98420X103 |
| — | MARINUS PHARMACEUTICALS INC | 5,724,235 | $14,540 | 1.5% | $6.30 | — | COM | 56854Q101 |
| — | SOLID BIOSCIENCES INC | 3,871,164 | $11,343 | 1.2% | $8.88 | — | COM | 83422E105 |